- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
J&J’s Lung Cancer Combo Outperforms Tagrisso in Survival Rates
Johnson & Johnson has achieved a breakthrough in the treatment of non-small cell lung cancer (NSCLC), with its combination therapy of Rybrevant and Lazcluze...Blueprint Terminates Clinical-Stage CDK2 Inhibitor Program but Continues Breast Cancer Research
Blueprint Medicines has announced the termination of its clinical-stage CDK2 inhibitor program, including the development of BLU-222, but reaffirmed its commitment to advancing preclinical...Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...
- Commercial
Tune Therapeutics Raises Whopping $175M to Bring Epigenetic Drug Into Clinic
Investors are clearly in no doubt over the functionality of Tune Therapeutics’ epigenetic silencing drug, providing the biotech with an astounding $175 million in...Gilead Sciences Broadens Scope with $1.7 Billion Partnership with Leo Pharma
Gilead Sciences is further extending its reach beyond its roots in infectious diseases, with a notable foray into oncology and, more recently, a deeper...Portage packages Tarus’ adenosine receptor antagonists into new business
Over two years after taking over Tarus Therapeutics, Portage Biotech is reintroducing Tarus’ adenosine receptor antagonists through a new company headed by a previous...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
- R&D
Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation
A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...Research finds Merck’s treatment of lung disease can lower chance of death
Mohsin Riaz - 0Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults
Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...Developments in RNA Research Win Nobel Prizes for the Second Consecutive Year
After last year’s Nobel Prize in Physiology or Medicine was awarded to Drew Weissman and Katalin Karikó for their work on mRNA vaccines, which...
- Clinical
J&J’s Lung Cancer Combo Outperforms Tagrisso in Survival Rates
Johnson & Johnson has achieved a breakthrough in the treatment of non-small cell lung cancer (NSCLC), with its combination therapy of Rybrevant and Lazcluze...Blueprint Terminates Clinical-Stage CDK2 Inhibitor Program but Continues Breast Cancer Research
Blueprint Medicines has announced the termination of its clinical-stage CDK2 inhibitor program, including the development of BLU-222, but reaffirmed its commitment to advancing preclinical...Sanofi and SK bioscience advance their 21-Valent vaccine to Phase 3
Sanofi has announced a new step forward in its collaboration with SK bioscience, providing a €50 million ($52 million) upfront payment to propel their...Corcept’s ALS Modulator Fails to Meet Primary Endpoint in Phase 2 Study
After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic lateral sclerosis (ALS) space. Results from its Phase 2 study, designed...
- Commercial
Tune Therapeutics Raises Whopping $175M to Bring Epigenetic Drug Into Clinic
Investors are clearly in no doubt over the functionality of Tune Therapeutics’ epigenetic silencing drug, providing the biotech with an astounding $175 million in...Gilead Sciences Broadens Scope with $1.7 Billion Partnership with Leo Pharma
Gilead Sciences is further extending its reach beyond its roots in infectious diseases, with a notable foray into oncology and, more recently, a deeper...Portage packages Tarus’ adenosine receptor antagonists into new business
Over two years after taking over Tarus Therapeutics, Portage Biotech is reintroducing Tarus’ adenosine receptor antagonists through a new company headed by a previous...
- Technology
Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances
Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal imbalances, resulting in irregular weight patterns. Wisp’s new weight care...PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm
Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...Elon Musk Announces Neuralink’s Second Brain-Computer Chip Implantation in a Patient
Neuralink, founded by Elon Musk, revealed that it has placed its device in the second human trial subject. The therapeutic application of the technology...AI Firm Formation Bags $372 Series D Funding
In 2024, megarounds have been extremely uncommon. Nonetheless, Formation Bio was able to secure a remarkable series D funding round of $372 million as...
- Insights
The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption
A new independent survey of senior US pharma regulatory professionals suggests that commitment to AI investment is much higher than might be expected, although...Improving life science R&D outcomes with AI
Ben Sidders - 0Maximizing the potential AI/data-driven model of drug discovery requires the technology’s full integration into R&D. Biorelate’s Dr Ben Sidders explains. Pharma R&D latest disruption is...The medical device sector’s surging regulatory burden: how are suppliers coping?
Regulators around the world are increasing their scrutiny of medical devices as these become more critical to patient outcomes. Referencing new research, Peter Muller...The Future of Gene Therapies: Three Trends
“Maps don’t show you where you will go in life, they show you where you might go.”—John Green Over...
- Podcast
- Awards
- More
Editor Picks
Rovi’s Expansion in Pharmaceutical Production with Moderna
The Laboratorios Farmacéuticos Rovi and Moderna partnership has recently achieved a milestone...
Bristol Myers invests $65 million to increase its portfolio of autoimmune products
Bristol Myers Squibb has invested $65 million in Repertoire Immune Medicines, betting on its...
Five Things to Know in October Third & Fourth Week
Good news for those with hearing difficulties- hearing aids are now available...
Must Read
J&J’s Lung Cancer Combo Outperforms Tagrisso in Survival Rates
Johnson & Johnson has achieved a breakthrough in the treatment of non-small cell lung...
Merck’s HPV Vaccine Gets Green Light From China Regulator
According to a statement released by Merck, its human papillomavirus vaccination (HPV) has been...
Tune Therapeutics Raises Whopping $175M to Bring Epigenetic Drug Into Clinic
Investors are clearly in no doubt over the functionality of Tune Therapeutics’ epigenetic silencing...
About Us
Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.
Contact us: reachout(at)lifescivoice.com